Status:
COMPLETED
The Immunogenicity and Safety of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell)
Lead Sponsor:
Institute of Medical Biology, Chinese Academy of Medical Sciences
Collaborating Sponsors:
Guangxi Center for Disease Control and Prevention
Conditions:
Poliomyelitis
Eligibility:
All Genders
2-4 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this Phase 2/3 trial is to assess the safety and immunogenicity of Live attenuated Poliomyelitis vaccine (human diploid cell)
Detailed Description
Live attenuated Poliomyelitis vaccine (human diploid cell) is used for poliovirus prevention in children above 2 years old , Which was developed by Institute of Medical Biology , Chinese Academy of Me...
Eligibility Criteria
Inclusion
- Only subjects fulfilling all of the following criteria will be eligible for the study:
- People aged from 2 months to 4 months old.
- The subjects or subjects' guardians are able to understand and sign the informed consent
- The subjects or subjects' guardians allow to comply with the requirements of the protocol
- Subjects with temperature \<=37.0°C on axillary setting
- The subjects have signed informed consent already
Exclusion
- The subjects have never been vaccinated with any Poliomyelitis Vaccine.
- \-
Key Trial Info
Start Date :
January 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT02231632
Start Date
January 1 2011
End Date
August 1 2012
Last Update
October 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Medical Biology -Chinese Academy of Medical Sciences Kunming, Yunnan, China 650118
Kunming, Yunnan, China, 650118